P655 Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn’s disease: Results from UniStar, a phase 1 study
ECCO'20 Vienna
2020
P656 Clinical implications of endoscopic submucosal dissection in management of patients with ulcerative colitis-associated dysplasia
ECCO'20 Vienna
2020
P658 A pooled analysis of serum phosphate measurements and transient decreased phosphate levels in 45 interventional trials with ferric carboxymaltose
ECCO'20 Vienna
2020
P659 The impact of total colectomy on the course of extraintestinal manifestations in Swiss IBD cohort study patients
ECCO'20 Vienna
2020
P660 Evaluating the effectiveness of disease assessment at 2 weeks following a course of oral steroids: Does early intervention affect outcomes?
ECCO'20 Vienna
2020
P661 Post-operative prophylaxis with anti-TNF in patients with Crohn’s disease who are anti-TNF experienced is associated with higher rates of prophylaxis failure
ECCO'20 Vienna
2020
P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
ECCO'20 Vienna
2020
P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies
ECCO'20 Vienna
2020
P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort
ECCO'20 Vienna
2020
P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study
ECCO'20 Vienna
2020
P666 Neutropenia in inflammatory bowel disease patients on TNF inhibitors: A single-centre, retrospective cohort study
ECCO'20 Vienna
2020
P667 Combined therapy of perianal fistulas with autologous adipose-derived stem cells
ECCO'20 Vienna
2020
P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study
ECCO'20 Vienna
2020
P669 Adherence to self-administered biologic therapies in inflammatory bowel disease: Experience in a tertiary hospital
ECCO'20 Vienna
2020
P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis
ECCO'20 Vienna
2020
P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study
ECCO'20 Vienna
2020
P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?
ECCO'20 Vienna
2020